ArticleBMC cancer2026

An integrated pathway mutation and clinical model predicts survival in unresectable HCC with hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab.

Shuangyan Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.